A review of 18 randomised controlled trials suggests that a mindfulness blood pressure benefit is real but dose-dependent: daily practice reinforced by weekly sessions over eight to 12 weeks produced the most consistent physiological improvements, according to research published in Elsevier‘s journal Cardiology Clinics.
The review, led by Rosalba (Rose) Hernandez, a professor of social work at the University of Illinois Urbana-Champaign and a Fellow of the American Heart Association, examined trials that tested positive psychology and mindfulness interventions designed to improve mental or physical health. The headline finding is straightforward: frequency of contact matters. Programs that kept participants engaged consistently outperformed those that did not.
What the trials actually showed about mindfulness blood pressure and inflammation
The studies generally enrolled groups of 50 to 200 adults who already had elevated cardiovascular risk, including uncontrolled hypertension or heart failure. Participants were usually in their late 50s to mid-60s. Among studies that reported gender, women made up 35 to 55% of participants.
Hernandez stated that mindfulness-based programmes delivered over an eight-week period reduced systolic blood pressure and lowered inflammatory markers such as high-sensitivity C-reactive protein and fibrinogen in hypertension and post-acute coronary syndrome cohorts. A 12-week spirituality-based digital intervention, she noted, achieved one of the larger reductions: systolic blood pressure fell by 7.6 points on a standard cuff, and central systolic pressure, measured in the aorta, fell by 4.1 points.
The programmes themselves varied considerably. Some used structured phone sessions, journaling paired with brief check-ins, or digital tools such as apps and text messages. Others ran interactive in-person group meetings, or hybrid approaches combining face-to-face activities with virtual sessions. Most included weekly sessions alongside tasks that participants completed at home, and the majority lasted between six and 12 weeks.
Daily practice, not just intention
One of the clearer practical conclusions from the review concerns what Hernandez called the “therapeutic dose.” Her team found that programs pairing daily microtasks with weekly sessions tended to produce the most reliable short-term physiological benefits. An eight-week WhatsApp-based programme, for instance, encouraged participants to become more physically active, improve their diets, and take their medications as prescribed.
The comparison between programme types is worth reading carefully. A programme that incorporated motivational interviewing increased cardiac patients’ activity by 1,800 steps per day and also improved medication adherence. Mindfulness programmes, by contrast, improved physical activity and diet but did not produce the same medication adherence benefit, according to the review. That is a distinction the study makes plainly, and it is worth preserving rather than flattening into a general endorsement of one approach over another.
On sustaining gains, Hernandez was measured: “Therapeutic dosing typically involved high-frequency dosing over this time period to obtain short-term physiologic benefits, while ongoing less-intensive contact may be needed to sustain behavioural change.” The review does not claim that eight weeks is enough to lock in results permanently.
Alyssa M. Vela, a professor of surgery and of psychiatry and behavioural sciences at Northwestern University Feinberg School of Medicine and a co-author, said the findings “further point to the importance of attending to mental and behavioural health for cardiovascular disease prevention and cardiovascular health optimisation,” and called for routine screening and integration of cardiac behavioural medicine. Katharine S. Edwards, a professor of cardiovascular medicine and of psychiatry and behavioural medicine at Stanford Medicine, and Soonhyung Kwon, a social work professor at the University of South Florida, were also co-authors.
The new paper builds on a prior study led by Hernandez, published in Health Behavior and Policy Review, which found that people with the highest levels of optimism tended to have healthier hearts. That earlier research was funded by the National Institutes of Health and the National Center for Research Resources.
The overall picture the review offers is one of cautious promise rather than established practice. The association between mindfulness blood pressure reduction and structured daily practice is consistent across trials, but the field, as Hernandez acknowledged, has not always clearly defined how frequently people need to practise, or for how long. This review is an attempt to answer that question. The answer it offers is: more often than most programmes have required, and with ongoing contact to sustain any behavioural shift. The American Heart Association has not yet incorporated these findings into formal clinical guidance, and whether health systems will move to embed cardiac behavioural medicine at scale remains an open question the review itself does not resolve.
